Alembic Pharmaceuticals Limited (NSE:APLLTD)
India
· Delayed Price · Currency is INR 968.90
-5.70 (-0.58%)
Jun 27, 2025, 3:29 PM IST
Alembic Pharmaceuticals Revenue
In the fiscal year ending March 31, 2025, Alembic Pharmaceuticals had annual revenue of 66.72B INR with 7.12% growth. Alembic Pharmaceuticals had revenue of 17.70B in the quarter ending March 31, 2025, with 16.65% growth.
Revenue
66.72B
Revenue Growth
+7.12%
P/S Ratio
2.85
Revenue / Employee
4.03M
Employees
16,571
Market Cap
190.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 66.72B | 4.43B | 7.12% |
| Mar 31, 2024 | 62.29B | 5.76B | 10.19% |
| Mar 31, 2023 | 56.53B | 3.47B | 6.54% |
| Mar 31, 2022 | 53.06B | -873.40M | -1.62% |
| Mar 31, 2021 | 53.93B | 7.87B | 17.10% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Alembic Pharmaceuticals News
- 10 days ago - Alembic Pharma receives EIR from USFDA for Karakhadi API-III facility - Business Upturn
- 11 days ago - Pharma stocks in focus as Trump announces tariffs on sector ‘soon’ - Business Upturn
- 26 days ago - Alembic Pharma shares dip over 2% after USFDA issues 4 observations for Panelav facility - Business Upturn
- 4 weeks ago - Alembic Pharmaceuticals shares in focus after USFDA nod for cancer drug Bosutinib - Business Upturn
- 5 weeks ago - Alembic Pharmaceuticals gets USFDA final approval for Amlodipine and Atorvastatin Tablets - Business Upturn
- 6 weeks ago - Alembic Pharma gets USFDA nod for Rivaroxaban tablets across four strengths; to launch 2.5 mg in Q1 FY26 - Business Upturn
- 7 weeks ago - Alembic Pharma Q4 profit falls 12%, revenue rises 17% - The Times of India
- 7 weeks ago - Alembic Pharmaceuticals shares drop 2% as Q4 net profit falls 11.9% YoY to Rs 156.89 crore - Business Upturn